New Pfizer Breakthrough Miraculously Extends Lifespan Of Near-Death Patents

Top Headlines

Recent News

Area Dad Thinks Refs Should Just Let Them Play Football

DOYLESTOWN, PA—Facetiously questioning how the game had suddenly become a non-contact sport, local father Aaron Harper confirmed his belief Thursday that referees officiating a Thanksgiving game between the Philadelphia Eagles and Detroit Lions should just let them play football out there.
End Of Section
  • More News
TV Listings
Just Like Everything Else!: Fox 8 p.m. EDT/7 p.m. ABC Pete's wife is still on him about building that darn shed, these kids are going to be the death of Sheila and Dave, and the hot next-door neighbor is up in EVERYBODY'S business! Sunday nights on ABC couldn't be any more familiar!

Special Coverage

Area Man

This Great Song, Bar Sources Report

TOMAH, WI—Pausing their conversations momentarily to call attention to the music playing on the establishment’s jukebox, sources at local bar Shepherd’s confirmed to reporters Friday that this is a great song.


New Pfizer Breakthrough Miraculously Extends Lifespan Of Near-Death Patents

NEW YORK—Hailing it as a groundbreaking discovery with far-ranging benefits, pharmaceutical company Pfizer announced a new breakthrough Friday that vastly extends the lifespan of near-death patents. “Ensuring that every one of these patents lives a long and fruitful life is our highest priority, and we’re committed to doing everything in our power to make sure they survive,” said Pfizer spokeswoman Ellen Hilty, noting that the drug manufacturer with more than $50 billion in annual revenues had assembled elite teams of experts and dedicated years of intense work to finding a way to prolong the lives of dying patents. “At Pfizer, patents always come first. Our primary goal is, and always will be, keeping them alive and healthy for as long as possible. And that’s why we couldn’t be happier to announce this wonderful development.” Hilty added that nothing causes Pfizer officials more distress than seeing a once robust patent expire at a young age, a “terrible tragedy” that allows dozens of generic manufacturers to copy it and offer pharmaceuticals to customers far more cheaply.